As supply chain issues sweep across the industry, Pfizer is warning about expected supply shortfalls of its penicillin offerings.
After the FDA first reported a nationwide penicillin shortage in April, Pfizer updated its hospital customers on the expected limited supply of its Bicillin prefilled syringes. The Pfizer antibiotic comes in a long-acting form or in a combination of two different penicillin types.
Pfizer attributes the supply hiccup to “complex combination” of factors, including “significant” demand increases and a rise in syphilis infection rates, the company’s hospital’s opioids and prefilled syringes director, Kevin Martyn, wrote in the update.
In response, the company has prioritized its manufacturing capacity of long-acting Bicillin to meet the spike in demand.
As it stands, all doses of the company’s combination penicillin syringes are expected to run out during this year’s third quarter. Supply of the long-acting version and its pediatric dosing will diminish by the end of the second quarter.
Read the full Fierce Pharma article>>
